Q-omics provides the consensus-scored RPL12P20 profile across patient tissues and cancer cell-line models. RPL12P20 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in TGCT. Among the 18 cancer types available for tumor–normal comparison, RPL12P20 is differentially expressed in 6, with the highest sampling consensus in READ. Additionally, RPL12P20 RNA expression shows 13,096 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight TGCT, READ, and GBM as cancer lineages where RPL12P20 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL12P20 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL12P20 survival associations across molecular data types. RPL12P20 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL12P20 RNA expression–survival associations across cancer types. High RPL12P20 expression shows unfavorable associations in TGCT, UCEC, DLBC, COAD and LAML, but favorable associations in MESO. The TGCT Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify TGCT as the clearest survival context for RPL12P20 RNA expression.
This table summarizes RPL12P20 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for RPL12P20. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL12P20 shows lower tumor expression in READ, LUSC, LUAD, THCA and ESCA and higher tumor expression in KICH. The READ box plot shows higher RPL12P20 RNA expression in normal versus tumor tissue (log2 FC = −0.156, t-test p = .002).
This table shows molecular features associated with RPL12P20 in patient tissues and cancer cell lines. In patient samples, RPL12P20 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
